Search research articles
Contact Us
Filters
Showing results (71-80 of 108) with videos related to
Page
of 11
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 15, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, et al.
Frontiers in Oncology
|
August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Frontiers in Oncology
|
November 15, 2021
Post-Induction Management in Patients With Left-Sided <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi, Alessio Cortellini, Olga Venditti, et al.
Frontiers in Oncology
|
January 3, 2022
Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)
Marco Rastrelli, Paolo Del Fiore, Irene Russo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry
Alessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Clinical Colorectal Cancer
|
August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study
Alessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
JHEP Reports : Innovation in Hepatology
|
January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Meng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Cancers
|
May 21, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study
Alessandro Parisi, Alessio Cortellini, Katia Cannita, et al.
Journal for Immunotherapy of Cancer
|
March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 108) with videos related to
Sort By:
Page
of 11
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 15, 2021
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Paolo Antonetti, Maria Concetta Fargnoli, Giampiero Porzio, et al.
Frontiers in Oncology
|
August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis
Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Frontiers in Oncology
|
November 15, 2021
Post-Induction Management in Patients With Left-Sided <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
Alessandro Parisi, Alessio Cortellini, Olga Venditti, et al.
Frontiers in Oncology
|
January 3, 2022
Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)
Marco Rastrelli, Paolo Del Fiore, Irene Russo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry
Alessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Clinical Colorectal Cancer
|
August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study
Alessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
JHEP Reports : Innovation in Hepatology
|
January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Meng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
Cancers
|
May 21, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study
Alessandro Parisi, Alessio Cortellini, Katia Cannita, et al.
Journal for Immunotherapy of Cancer
|
March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Page
of 11